Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
Recruiting
Observational Study
Gastric Cancer
Immunotherapy
Adverse Event
Metabonomics
Lipidomics
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Qinghai Red Cross Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study comprehensively examines metabolic and lipidomic dynamics in gastric cancer patients initiating PD-1/PD-L1 inhibitor therapy, employing a longitudinal design with pre- and post-treatment patients. The primary objectives include identifying irAE-associated metabolic and lipid biomarkers, developing predictive risk models, and evaluating the prognostic value of these molecular profiles. T…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age≥ 18 years
* ECOG PS 0-2
* Gastric cancer diagnosed by histology or cytology
* Untreatment with PD-1/PD-L1 inhibitors
* Expected survival≥3 months
* Exhibits a favorable adherence to treatment and follow-up,demonstrates compliance with the…
Contacts
No contact information available.